There is accumulating evidence that the kallikrein–kinin system is critically involved in various brain diseases (e.g., stroke, multiple sclerosis, Alzheimer’s disease, epilepsy, depression) and its modulation might be a promising strategy to combat these diseases. Here, KLK4 is linked to depressive symptom measurement.